Fig. 1From: Identifying an early treatment window for predicting breast cancer response to neoadjuvant chemotherapy using immunohistopathology and hemoglobin parametersBox plot of mean maximum total hemoglobin (tHb; μmol/L) of two responder groups of Miller-Payne (MP) 4–5 and MP 1–3 measured at baseline, day 7, and at the end of cycles (cyc) 1, 2, and 3 of NACBack to article page